| Statins impair antitumor effects of rituximab by inducing conformational changes of CD20 M Winiarska, J Bil, E Wilczek, GM Wilczynski, M Lekka, PJ Engelberts, ... PLoS medicine 5 (3), e64, 2008 | 158 | 2008 |
| Cardiotoxicity of the anticancer therapeutic agent bortezomib D Nowis, M Mączewski, U Mackiewicz, M Kujawa, A Ratajska, ... The American journal of pathology 176 (6), 2658-2668, 2010 | 148 | 2010 |
| Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response A Szokalska, M Makowski, D Nowis, GM Wilczynski, M Kujawa, C Wójcik, ... Cancer research 69 (10), 4235-4243, 2009 | 126 | 2009 |
| Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice D Nowis, M Bugajski, M Winiarska, J Bil, A Szokalska, P Salwa, T Issat, ... BMC cancer 8, 1-12, 2008 | 83 | 2008 |
| Molecular mechanisms of the antitumor effects of anti-CD20 antibodies M Winiarska, E Glodkowska-Mrowka, J Bil, J Golab Front Biosci (Landmark Ed) 16 (1), 277-306, 2011 | 67 | 2011 |
| Statins impair glucose uptake in tumor cells A Malenda, A Skrobanska, T Issat, M Winiarska, J Bil, B Oleszczak, ... Neoplasia 14 (4), 311-323, 2012 | 65 | 2012 |
| Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity J Bil, M Winiarska, D Nowis, K Bojarczuk, A Dabrowska-Iwanicka, ... Blood, The Journal of the American Society of Hematology 115 (18), 3745-3755, 2010 | 60 | 2010 |
| Statins use and cancer: an update M Zaleska, O Mozenska, J Bil Future Oncology 14 (15), 1497-1509, 2018 | 54 | 2018 |
| Optical coherence tomography criteria for defining functional severity of intermediate lesions: a comparative study with FFR T Pawlowski, F Prati, T Kulawik, E Ficarra, J Bil, R Gil The International Journal of Cardiovascular Imaging 29, 1685-1691, 2013 | 52 | 2013 |
| Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro J Bil, L Zapala, D Nowis, M Jakobisiak, J Golab Cancer letters 288 (1), 57-67, 2010 | 42 | 2010 |
| Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM (R) stent: the randomised, multicentre, open-label, controlled POLBOS II trial RJ Gil, J Bil, MJ Grundeken, A Kern, LA Inigo Garcia, D Vassilev, ... EuroIntervention 12 (11), e1404-e1412, 2016 | 41 | 2016 |
| Dedicated bifurcation paclitaxel‐eluting stent BiOSS Expert® in the treatment of distal left main stem stenosis J Bil, RJ Gil, D Vassilev, J Rzezak, T Kulawik, T Pawlowski Journal of Interventional Cardiology 27 (3), 242-251, 2014 | 40 | 2014 |
| Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo T Issat, D Nowis, M Legat, M Makowski, MP Klejman, J Urbanski, ... International journal of oncology 30 (6), 1413-1425, 2007 | 39 | 2007 |
| The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review KE Gil, A Pawlak, RJ Gil, M Frontczak-Baniewicz, J Bil Advances in medical sciences 61 (2), 331-343, 2016 | 37 | 2016 |
| Regular drug-eluting stent vs dedicated coronary bifurcation bioss expert stent: multicenter open-label randomized controlled POLBOS I trial RJ Gil, J Bil, V Džavík, D Vassilev, A Kern, R Formuszewicz, ... Canadian Journal of Cardiology 31 (5), 671-678, 2015 | 35 | 2015 |
| Intravascular lithotripsy for the treatment of stent underexpansion: the multicenter IVL-DRAGON registry W Wańha, M Tomaniak, P Wańczura, J Bil, R Januszek, R Wolny, ... Journal of Clinical Medicine 11 (7), 1779, 2022 | 30 | 2022 |
| First‐in‐man study of dedicated bifurcation sirolimus‐eluting stent: 12‐month results of BiOSS LIM® registry RJ Gil, J Bil, D Vassiliev, LA Inigo Garcia Journal of Interventional Cardiology 28 (1), 51-60, 2015 | 29 | 2015 |
| Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity M Winiarska, D Nowis, J Bil, E Glodkowska-Mrowka, A Muchowicz, ... Journal of Biological Chemistry 287 (38), 31983-31993, 2012 | 29 | 2012 |
| Platelet distribution width as the prognostic marker in coronary bifurcation treatment A Kern, RJ Gil, K Bojko, E Sienkiewicz, B Januszko‐Giergielewicz, ... European Journal of Clinical Investigation 47 (7), 524-530, 2017 | 28 | 2017 |
| Carcinoid heart disease: how to diagnose and treat in 2020? B Bober, M Saracyn, M Kołodziej, Ł Kowalski, E Deptuła-Krawczyk, ... Clinical Medicine Insights: Cardiology 14, 1179546820968101, 2020 | 26 | 2020 |
Jakub GolabMedical University of Warsaw, PolandVerified email at wum.edu.pl
